Business, energy, technology, markets and global industry news from Business News Today

Full-Life Technologies

PharmaDeviceNews Full-Life Technologies
Radiopharmaceutical cancer therapy advances as the US Food and Drug Administration clears Full-Life’s actinium-225 FL-261 for Phase 1 clinical testing in c-MET-positive lung cancer, expanding the company’s targeted oncology pipeline. Representative image.
Pharma & Biotech

Full-Life wants to carry actinium-225 directly to c-MET tumors. Can FL-261 widen targeted alpha therapy beyond prostate cancer?

FDA clears Full-Life’s actinium-225 FL-261 for Phase 1 testing in c-MET-positive lung cancer as the radiopharmaceutical company expands its pipeline.

Read More
Pharma & Biotech

How Full-Life Technologies is using US$150m to push beyond platform promise

Radiopharma needs more than promising targets. Full-Life’s US$150m raise puts actinium-225 supply and clinical execution in focus.

Read More